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Defective Cell Cycle Checkpoint Functions in
Melanoma Are Associated with Altered Patterns
of Gene Expression
William K. Kaufmann1,2,3, Kathleen R. Nevis1, Pingping Qu4, Joseph G. Ibrahim2,3,4, Tong Zhou1,
Yingchun Zhou1, Dennis A. Simpson1, Jennifer Helms-Deaton1, Marila Cordeiro-Stone1,2,3,
Dominic T. Moore2, Nancy E. Thomas2,5, Honglin Hao5, Zhi Liu5, Janiel M. Shields5,6, Glynis A. Scott7
and Norman E. Sharpless2,8,9
Defects in DNA damage responses may underlie genetic instability and malignant progression in melanoma.
Cultures of normal human melanocytes (NHMs) and melanoma lines were analyzed to determine whether
global patterns of gene expression could predict the efficacy of DNA damage cell cycle checkpoints that arrest
growth and suppress genetic instability. NHMs displayed effective G1 and G2 checkpoint responses to ionizing
radiation-induced DNA damage. A majority of melanoma cell lines (11/16) displayed significant quantitative
defects in one or both checkpoints. Melanomas with B-RAF mutations as a class displayed a significant defect in
DNA damage G2 checkpoint function. In contrast the epithelial-like subtype of melanomas with wild-type
N-RAS and B-RAF alleles displayed an effective G2 checkpoint but a significant defect in G1 checkpoint function.
RNA expression profiling revealed that melanoma lines with defects in the DNA damage G1 checkpoint
displayed reduced expression of p53 transcriptional targets, such as CDKN1A and DDB2, and enhanced
expression of proliferation-associated genes, such as CDC7 and GEMININ. A Bayesian analysis tool was more
accurate than significance analysis of microarrays for predicting checkpoint function using a leave-one-out
method. The results suggest that defects in DNA damage checkpoints may be recognized in melanomas
through analysis of gene expression.
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INTRODUCTION
During the period 1973–1999, the incidence rate for mela-
noma among Caucasian American men 465 years of age
rose over four-fold from 20 to 90 per 100,000 and the death
rate doubled (Geller et al., 2002). Sunlight, or solar radiation,
is an important etiologic factor, with epidemiologic studies
indicating that severe childhood sunburns contribute the
greatest risk (Gilchrest et al., 1999). There is also genetic
susceptibility to melanoma as demonstrated by several fami-
lial cancer syndromes, xeroderma pigmentosum (Kraemer
et al., 1989), familial atypical mole and malignant melanoma
syndrome (Gibbs et al., 2002), retinoblastoma (Fletcher et al.,
2004), and Li–Fraumeni syndrome (Cohen et al., 2005).
Melanomagenesis is associated with defects in nucleotide
excision repair of solar radiation-induced DNA damage, as in
xeroderma pigmentosum, and cell cycle checkpoints that
arrest growth after DNA damage and oncogene activation, as
in familial atypical mole and malignant melanoma syndrome,
retinoblastoma, and Li–Fraumeni syndrome. Lastly, MC1R
polymorphisms (associated with red hair and freckling) are
also associated with melanoma risk (Pho et al., 2006).
Somatic mutations in B-RAF or N-RAS are key genetic
alterations that contribute to development of melanoma
(Eskandarpour et al., 2003; Smalley and Herlyn, 2004).
Activating mutations in these genes are comparatively
common in melanoma, with about 50–75% of melanomas
having mutations in B-RAF and 10–15% having mutations in
N-RAS (Daniotti et al., 2004; Thomas et al., 2004). A recent
molecular epidemiologic study of melanoma in North
Carolina identified a significant association of these onco-
gene mutations with age (Thomas et al., 2007). Although
clinically similar in terms of progression and vertical growth,
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melanomas with B-RAF mutations appeared 15 years earlier
than melanomas with N-RAS mutations. Mutations in these
genes also occur very early in melanomagenesis, as similar
frequencies of melanocytic nevi and melanomas express
these mutant oncogenes (Kumar et al., 2004).
Mutations in N-RAS and B-RAF may stimulate growth, in
part, through activation of ERK1/2 (Satyamoorthy et al., 2003;
Shields et al., 2007) and enhance genetic instability by
attenuation of cell cycle checkpoint function. DNA double-
strand breaks (DSBs) are known to activate a cell cycle
checkpoint response that blocks progression of G2 cells into
mitosis (G2 checkpoint) (Paules et al., 1995). Mitotic entry
normally requires activation of cyclin B1/Cdk1 kinase activity
(mitosis-promoting factor) within the interphase nucleus. In
response to DNA DSB, ataxia telangiectasia-mutated (ATM),
and ATM and rad3-related (ATR)-dependent activation of
Chk1 leads to inhibition of mitosis-promoting factor and
inhibition of Plk1 prevents the accumulation of mitosis-
promoting factor within the nucleus (reviewed in Kaufmann
et al., 2002). Ras oncogenes have been reported to enhance
expression of cyclin B1 and cyclin-dependent kinase 1
(Santana et al., 2002), and to attenuate G2 checkpoint function
(Agapova et al., 2004; Knauf et al., 2006). Thus, expression of
oncogenic N-RAS and B-RAF may attenuate G2 checkpoint
function in cells with defects in p16 and p53, thereby
enhancing genetic instability in cells with DNA damage.
Although p53 mutations are comparatively rare in
sporadic melanoma, the demonstration of UV signature
mutations in p53 in melanomas from xeroderma pigmento-
sum patients indicates that melanocyte p53 is a target of UV
and suggests that p53 signaling suppresses melanomagenesis
(Giglia-Mari and Sarasin, 2003). A recent report showed that
inactivation of p53 cooperates with induction of telomerase
and oncogenic N-RAS to induce melanomas in human
xenobiotic skin grafts (Chudnovsky et al., 2005). Alterations
in the p53 signaling pathway could contribute to melanoma
genesis through attenuation of DNA repair, cell cycle
checkpoint function, or apoptosis (Kastan and Bartek,
2004), leading to enhanced mutation and reduced cell death.
p53 function is regulated by ARF, a second product of the
CDKN2A/INK4A locus that is commonly deleted in melanoma
(Grafstrom et al., 2005).
Recent studies demonstrate that melanomas and melanoma
cell lines display large numbers of nuclear foci that are
positive for phospho-histone H2AX as a marker of replication
stress and DNA DSBs (Gorgoulis et al., 2005; Warters et al.,
2005). Melanomas also display severe chromosomal instabil-
ity, with many amplifications and deletions, as determined by
array comparative genomic hybridization (Bauer and Bastian,
2006). As the p53-dependent G1 checkpoint should arrest the
growth of cells with DNA DSBs, these results suggest that
inactivation of G1 checkpoint function may be common in
melanoma, permitting melanoma cells to proliferate with
broken and rearranged chromosomes (Gorgoulis et al., 2005).
How the DNA damage signal is ignored in melanomas with
wild-type p53 is unknown.
Analysis of global gene expression through microarray
technology can discover patterns of co-regulated genes that
reveal unanticipated biological relationships. The basal cell
subtype of breast cancer was discovered in this way
(Alizadeh et al., 2005). Several studies have examined the
global patterns of gene expression in melanomas (Seykora
et al., 2003; Hoek et al., 2004; Haqq et al., 2005; Nambiar
et al., 2005; Shields et al., 2007). These studies showed an
association of TWIST expression with epithelial–mesenchymal
transition and worsened outcome (Hoek et al., 2004),
identified a large suite of genes regulated by the extracellular
signal-regulated kinase ERK (Shields et al., 2007), and
established the occurrence of an epithelial-like subtype of
melanoma with wild-type N-RAS and B-RAF proto-onco-
genes (Bloethner et al., 2005; Shields et al., 2007). In this
study, the patterns of gene expression in melanoma cell lines
were analyzed and correlated with quantitative variation in
DNA damage checkpoint function. We were interested in
whether patterns of gene expression could be used to identify
melanomas with defects in DNA damage checkpoint func-
tion. The results show that melanoma cell lines with defective
G1 and G2 checkpoint functions can often be recognized by
their patterns of gene expression in the basal, undamaged
state.
RESULTS
DNA damage cell cycle checkpoint function was quantified
in secondary cultures of normal human melanocytes (NHMs)
and in the melanoma cell lines detailed in Table 1. Because
DNA DSBs appear to be a feature of early and late stages of
melanomagenesis (Bartkova et al., 2005; Warters et al.,
2005), we considered it appropriate to use ionizing radiation
(IR) to induce DNA DSBs in melanocytes and melanoma cell
lines. DNA damage checkpoints acting in G1 and G2 cells
were analyzed for functional activity using flow cytometric
assays. By monitoring efficacy using quantitative assays of
cell cycle arrest in response to DNA DSBs, melanoma lines
with defective checkpoint function were identified and
metrics that estimated the degree of dysfunction were
generated.
NHMs express a functional DNA damage G1 checkpoint
DNA damage G1 checkpoint function was quantified by
treating cells with 1.5 Gy IR (or sham treatment for control)
and then labeling cells with BrdU for 2 hours beginning
6 hours post-treatment. S phase nuclei that incorporated BrdU
into DNA were stained with a fluorescein-labeled anti-BrdU
antibody and counterstained with propidium iodide. Two-
channel flow cytometry was performed to quantify the
fraction of cells in the first half of the S phase; such cells
had 2–3N DNA content and positive labeling with BrdU. The
IR-induced reduction in the percentage of cells in the first half
of S provides a quantitative index of G1 checkpoint function
(Doherty et al., 2003). Foreskin fibroblasts with effective G1
checkpoint function (NHF1-hTERT) displayed 490% reduc-
tion in the fraction of cells in early S phase, 6–8 hours after
irradiation, as irradiated G1 cells delayed entry into S phase
(Figure 1a). NHMs also displayed a significant reduction in
the fraction of cells in the first half of S phase, after treatment
with IR (Figure 1a). The degree of inhibition in NHMs
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averaged 57%, in the range previously reported for cultures
of human bladder epithelial cells (Doherty et al., 2003).
Expression of a dominant-negative p53 allele (p53H179Q) or
HPV16E6 in the NHM-2 melanocytes by retroviral gene
transfer ablated the IR-induced G1 arrest (NHM-2-179,
NHM-2-E6; Figure 1b). These results indicated that NHMs
express an effective p53-dependent G1 checkpoint response
to IR-induced DNA damage.
Western immunoblot was used to monitor checkpoint
signaling in response to DNA damage in the NHM-4
melanocyte culture. Cells were harvested 2, 6, and 24 hours
after 1.5 Gy, or 6 hours after sham treatment as the control.
After quantification of protein concentrations, equal amounts
of protein were separated by SDS-polyacrylamide gel electro-
phoresis. The NHM-4 preparation expressed the checkpoint
kinases, ATM, ATR and the effector of G1 checkpoint func-
tion, p53 (Figure 2). There was little change in p53 protein
after IR treatment although there was a clear induction of
phosphorylation at ser-15 in p53, which appeared to peak at
2 hours and diminish by 24 hours after IR. This phosphory-
lation of p53 is ATM-dependent in IR-treated normal human
fibroblasts (Kaufmann et al., 2003). NHM-4 also expressed
the checkpoint-transducing kinases Chk1 and Chk2. Treat-
ment with IR produced little phosphorylation of Chk1 at
ser-317, but strong phosphorylation of Chk2 at ser-68. This
IR-induced phosphorylation of Chk2 is also ATM dependent
(Brown et al., 1999). The NHM-4 cells expressed p21Waf1 and
p16; p21Waf1 was induced 2, 6, and 24 hours after IR while
p16 appeared to be induced by IR modestly at 24 hours.
These results indicated that ATM signaling to p53 and Chk2,
as well as induction of p21Waf1, was effective in the IR-treated
NHM-4 melanocyte strain.
Defective G1 checkpoint function in melanoma cell lines
Melanoma cell lines displayed a continuous range of res-
ponses to IR, with two lines delaying S phase entry by 75%
and five lines displaying less than 10% inhibition of S phase
Table 1. Sources of melanoma cell lines and their N-
RAS/B-RAF mutation status
Melanoma line N-RAS B-RAF Source
PMWK WT WT J Arbiser (Emory)
Mel505 WT WT J Hansson (Karolinska)
SK-Mel-187 WT WT A Houghton (Sloan Kettering)
RPMI8322 WT WT J Hansson (Karolinska)
SK-Mel-173 Q61K WT A Houghton (Sloan Kettering)
VMM39 Q61K WT C Slingluff (UVA)
Mel224 Q61R WT J Hansson (Karolinska)
SK-Mel-103 Q61R WT A Houghton (Sloan Kettering)
SK-Mel-147 Q61R WT A Houghton (Sloan Kettering)
SK-Mel-119 Q61R WT A Houghton (Sloan Kettering)
UACC257 WT V600E M Soengas (U Michigan)
A375 WT V600E J Arbiser (Emory)
WM2664 WT V600D J Arbiser (Emory)
A2058 WT V600E J Arbiser (Emory)
SK-Mel-24 WT V600E American Type Culture Collection
SK-Mel-28 WT V600E American Type Culture Collection
WT, wild type.
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Figure 1. G1 checkpoint function in NHMs and melanoma cell lines.
(a). Flow cytometric analysis of BrdU incorporation versus DNA content.
Normal human fibroblasts (F1-hTERT) and melanocytes (NHM-2) were
incubated with BrdU at 6–8 hours after 1.5 Gy IR or sham treatment, and then
processed for analysis of the fraction of cells in the first half of S phase
(BrdU-labeled and 2–3N DNA content, enclosed by boxes). The IR-induced
reduction in this fraction was a quantitative measure of DNA damage
G1 checkpoint function. (b) Quantification of G1 checkpoint function in
fibroblasts, melanocytes, and melanoma lines. Cells were treated with
1.5 Gy IR. The fraction of IR-treated cells in the first half of S phase, 6–8 hours
after treatment, was expressed as a percentage of the sham-treated control
as a quantitative index of G1 checkpoint function. Results represent the mean
percent of control; error bars enclose one standard deviation above the
mean (n¼ 2–5). *Po0.05 versus NHMs, by Dunnett’s t-test, with adjustment
for multiple comparisons; #Po 0.05 versus NHM-2 (Student’s t-test).
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entry (Figure 1b). Statistical evaluation of the data set
indicated that 10 of the 16 melanoma lines displayed a
defective G1 checkpoint response to IR-induced DNA damage
in comparison to NHMs (Table 2).
Western immunoblot analysis was performed on six
melanoma lines that were compared to normal human
fibroblasts (F1-hTERT) for their response to IR-induced DNA
damage. This analysis included two melanoma lines with
wild-type N-RAS and B-RAF alleles (RPMI8322 and SK-Mel-
187), two lines with mutant B-RAF (SK-Mel-24 and A2058),
and two with mutant N-RAS (SK-Mel-173 and -103). Protein
was quantified in cell lysates and equal amounts were loaded
for electrophoretic separation on polyacrylamide gels. Levels
of expression of proteins and specific post-translational
modifications were quantified by densitometry and the
relative pixel intensities were normalized to the F1-hTERT
sham (included on every blot). This analysis revealed
substantial variation among melanoma lines in the levels of
expression of checkpoint-associated proteins and their post-
translational modifications.
Protein expression within the G1 checkpoint signaling
pathway (Figure 3) was well correlated with functional
capacity (Figure 1b). Two G1 checkpoint-defective melano-
mas (RPMI8322 and SK-Mel-187) displayed enhanced
expression of p53, suggestive of inactivating mutations that
increase protein half-life, with little or no induction of
p21Waf1 post-IR. The G1 checkpoint-defective A2058 line
expressed nearly normal levels of p53, which was phos-
phorylated at ser-15 after treatment with IR. However, this
line overexpressed p16 substantially and did not express
p21Waf1. The line may grow in the presence of high levels of
p16, because RB function is defective (Noonan et al., 2005).
The defects in both RB and p21Waf1 can explain the defect
in G1 checkpoint function in the A2058 line. Two lines
had effective G1 checkpoint function (SK-Mel-24 and -173);
these lines activated p53 through phosphorylation of ser-15
and induced p21Waf1 after treatment with IR. SK-Mel-103
displayed a moderate but significant attenuation of G1
checkpoint function. ATM expression appeared to be
reduced in this line, and although p53 was activated by IR,
induction of p21Waf1 by IR was delayed. There was little
induction at 2 and 6 hours, and only a modest two-fold
induction at 24 hours after irradiation. Among the six
melanomas tested, four expressed no detectable p16 and
one expressed very high levels. These results are consistent
with the common inactivation of the p16/RB pathway in
melanoma. The two G1 checkpoint-effective melanomas (SK-
Mel-173 and -24) displayed normal signaling through p53 to
p21Waf1. As these lines did not express p16, the results
confirm that p16 is not required for G1 checkpoint response
to IR-induced DNA damage.
NHMs express a functional DNA damage G2 checkpoint
DNA damage G2 checkpoint function was scored by moni-
toring a mitosis-specific form of phospho-histone H3, using a
fluoresceinated antibody (Figure 4a). Mitotic cells with 4N
NHM4
Hrs after IR S 2 6 24
ATM
ATR
p53
p21
p16
P-p53
ser 15
Chk1
Chk2
P-Chk2
P-Chk1
Figure 2. Western immunoblot analysis of checkpoint protein expression in
NHMs. NHM-4 cells were treated with 1.5 Gy IR then harvested 2, 6, and
24 hours later. Controls (S) were harvested 6 hours after sham treatment.
Protein concentration in cell lysates was determined, so that equal protein
was loaded for separation by SDS-polyacrylamide gel electrophoresis.
Proteins were transferred to nitrocellulose membranes and probed for
expression of various checkpoint proteins.
Table 2. DNA damage checkpoint function in
melanoma cell lines
Melanoma line Mutation status G1 checkpoint G2 checkpoint
PMWK WT Defective Effective
Mel505 WT Defective Effective
SK-Mel-187 WT Defective Effective
RPMI8322 WT Defective Effective
Mel224 N-RAS Defective Effective
SK-Mel-119 N-RAS Defective Effective
SK-Mel-103 N-RAS Defective Effective
SK-Mel-147 N-RAS Effective (Effective)1
SK-Mel-173 N-RAS Effective Defective
VMM39 N-RAS Defective (Effective)
SK-Mel-24 B-RAF Effective (Effective)
A375 B-RAF Effective Effective
WM2664 B-RAF Effective (Effective)
UACC257 B-RAF Effective (Effective)
SK-Mel-28 B-RAF Defective Defective
A2058 B-RAF Defective Defective
WT, wild type.
1The qualification of checkpoint status as (Effective) denotes melanoma
cell lines that were significantly different (Po0.05) than NHMs when
adjustments for multiple comparisons were not made.
178 Journal of Investigative Dermatology (2008), Volume 128
WK Kaufmann et al.
Checkpoint Defects in Melanoma
DNA content stained positively with this antibody, allowing
their quantification by flow cytometry. Normal human fibro-
blasts (F1-hTert) responded to 1.5 Gy IR, with 495% inhi-
bition of mitosis, as cells in G2 delayed entry into mitosis,
and mitotic cells completed cell division and entered
G1. Similarly, irradiation of the NHM-2 melanocyte strain
produced 490% inhibition of mitosis (Figure 4a and b).
Secondary cultures of NHMs responded to IR, with a mean
90% inhibition of mitosis, indicative of effective DNA
damage G2 checkpoint function (Figure 4b).
Defective G2 checkpoint function in melanoma lines with
mutant B-RAF
As was seen for the G1 checkpoint response, melanoma
cell lines displayed a continuous range of G2 checkpoint
response to IR, with some lines inhibiting mitosis by 495%
and one line inhibiting mitosis by o40% (Figure 4b). In
comparison to the average response in NHMs, three of 16
melanoma lines displayed a statistically significant defect in
DNA damage G2 checkpoint function (Po0.05 after correc-
tion for multiple comparisons). Five other lines (SK-Mel-147,
SK-Mel-24, UACC257, VMM39, and WM2664) displayed a
significant (Po0.05) defect in G2 checkpoint function in
comparison to NHMs, when the analysis was not corrected
for multiple comparisons (Table 2). Analysis of ATM, ATR,
Chk1, NBS1, and Myt1 protein expression in the melanoma
lines depicted in Figure 3 did not reveal clear differences that
could explain the variation in G2 checkpoint function among
the lines.
Association between N-RAS and B-RAF mutations and DNA
damage checkpoint function
Activated mutant Ras oncogenes have been shown to atte-
nuate DNA damage G2 checkpoint function (Agapova et al.,
2004), and melanomas commonly harbor mutations in
N-RAS or its downstream effector B-RAF. To determine
whether the variation in checkpoint function among mela-
nomas was related to mutations in these components of the
mitogen-activated protein kinase signaling pathway, N-RAS
and B-RAF alleles were sequenced at the codons that are
typically mutated in melanomas (Thomas et al., 2007). This
analysis identified two highly significant associations be-
tween checkpoint function and oncogene mutation status
(Figure 5). As a class, melanoma lines with wild-type N-RAS
and B-RAF alleles displayed effective G2 checkpoint res-
ponse to IR, with o5% of G2 cells evading the checkpoint.
This same class of melanomas displayed a defective G1
checkpoint response to IR, with 490% of G1 cells evading
the checkpoint. As a class, melanomas with a mutant B-RAF
allele displayed an effective G1 checkpoint response to IR.
However, these lines displayed significantly attenuated G2
checkpoint function, with an average of 38% of G2 cells
evading the checkpoint. The class of melanomas with a
mutant N-RAS allele displayed an average of 21% of G2 cells
evading the checkpoint, a moderate but insignificant
attenuation in comparison to NHMs. This class of melanomas
also displayed variable G1 checkpoint response that was not
significantly different from NHMs.
Defects in cell cycle checkpoint function were compara-
tively common in melanoma cell lines, supporting the
hypothesis that genetic instability in melanoma may be due
in part to defects in the system of response to DNA damage
(Table 2). Defects in checkpoint function did not appear to
sort randomly among the melanoma lines. For example, the
four melanoma lines with wild-type N-RAS and B-RAF alleles
and effective DNA damage G2 checkpoint function all
displayed defective DNA damage G1 checkpoint function.
These results suggest that defects in G1 and G2 checkpoints
arise in melanomas from separate genetic alterations. Thus,
there are at least two ways that DNA damage checkpoint
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Figure 3. Immunoblot analysis of G1 checkpoint protein expression in melanoma lines. Details of cell treatment and analysis of protein expression are
as in the legend to Figure 2. NHF1-hTERT cells were included as a normalization control in all analyses. This figure represents a composite of results from
three different membranes. Below each immunoblot image are depicted pixel intensity values relative to the sham-treated NHF1-hTERT control that was
included on the same membrane. Only a representative image of the fibroblast controls is shown. Mutation status at the B-RAF and N-RAS loci and G1
checkpoint function are indicated for each cell line below and above the composite image, respectively.
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function can be disturbed during the development of mela-
noma, inactivation of G1 checkpoint independent of B-RAF
and N-RAS mutations, and attenuation of G2 checkpoint
associated with B-RAF mutations.
Signatures of defective DNA damage checkpoint function
Having established the occurrence of functional defects in
DNA damage cell cycle checkpoints in melanoma lines,
global gene expression was evaluated to search for signatures
that were associated with the defects. The 44K Agilent human
oligonucleotide microarray was used for expression profiling
and each cell line was analyzed once. We have previously
reported that the melanoma lines with wild-type N-RAS and
B-RAF alleles displayed a unique signature of gene expres-
sion in comparison to the lines with mutations in N-RAS and
B-RAF (Shields et al., 2007). The oncogene mutations were
associated with high levels of phospho-ERK1/2 and enhanced
expression of 4100 ERK1/2-responsive mRNAs. Statistical
evaluation of the microarray data sets also identified gene sets
that were associated with the functional activity of DNA
damage checkpoints.
Two methods of analysis tested for genes that varied
among the NHM strains and melanoma lines according to the
efficacy of checkpoint function. Significance analysis of
microarrays (SAM) (Tusher et al., 2001) has been commonly
applied to microarray data to identify genes that are corre-
lated with selected treatments or cell types. A new method
based on Bayesian statistical theory was developed. Check-
point function was evaluated as a binary variable to compare
lines with checkpoint responses greater and less than the
median response, using the quantitative data (Figures 1b
and 4b).
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Figure 4. DNA damage G2 checkpoint function in NHMs and melanoma
lines. (a) Flow cytometric quantification of the percentage of mitotic cells with
4N DNA content and expression of phospho-histone H3 (enclosed by boxes).
Normal human fibroblasts (NHF1-hTERT) and melanocytes (NHM-2) were
treated with 1.5 Gy IR or sham treated, then harvested 2 hours later for
quantification of mitotic cells. The IR-induced reduction in the fraction of
mitotic cells was used as a quantitative measure of DNA damage G2
checkpoint function. (b) Quantification of DNA damage G2 checkpoint
function in fibroblasts, melanocytes, and melanoma lines. The fraction of
IR-treated cells in mitosis 2 hours after treatment was expressed as a
percentage of the sham-treated control as a quantitative index of G2
checkpoint function. Results represent the mean percent of control; error bars
enclose one standard deviation above the mean (n¼ 2–7). *Po0.05 versus
NHMs, by Dunnett’s t-test, with adjustment for multiple comparisons.
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Figure 5. Defective DNA damage checkpoint function in melanoma
subtypes based on oncogene mutation status. DNA damage G1 (a) and G2
(b) checkpoint functions were quantified in normal human fibroblasts
(NHF, n¼3), ataxia telangiectasia fibroblasts (AT, n¼ 3), normal human
melanocytes (NHM, n¼5), melanoma lines with wild-type N-RAS and B-RAF
(WT, n¼ 4), melanoma lines with mutant N-RAS (NRAS, n¼ 6), and
melanoma lines with mutant B-RAF (BRAF, n¼ 6). After log-transformation of
data, class averages were compared by Student’s t-test.
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For the analysis of G1 checkpoint function in melano-
cytes and melanomas, SAM identified 26 genes that were
significantly different in the two classes (false discovery rate
(FDR) o0.1), while the Bayesian analysis identified 166
genes that were significantly different (FDR¼ 0.05) (the gene
lists are given in the Supplementary Table S1). Genes on both
lists included the well-established p53 target genes CDKN1A
(p21Waf1) and DDB2, which were expressed at lower levels in
G1 checkpoint-defective melanomas. Several cell prolifera-
tion-associated genes identified in the Bayesian list were
expressed at higher levels in G1 checkpoint-defective lines,
including CDC7, CKS1, cyclin B1, CDC2, GEMININ, RPA3,
and RFC4. Hierarchical clustering of the gene lists indicated
that both methods accurately separated the melanoma lines
according to G1 checkpoint function (Figure 6).
A leave-one-out procedure was employed to determine
the predictive efficacy of the two analysis tools. The data set
was repeatedly queried with one sample removed using the
binary analysis, to generate lists of genes that distinguished
checkpoint-effective and -defective lines, and then the
withheld sample was tested to see if it segregated with the
appropriate centroid (Tibshirani et al., 2002). The Bayesian
analysis tool with an FDR of 0.05 assigned the left-out sample
to the appropriate centroid in 78% of tests. SAM with an FDR
ofo0.1 assigned the left-out sample correctly in 69% of tests.
Both tools incorrectly classified G1 checkpoint function in
the NHM2 lines with expression of HPV16E6 or p53H179Q
to inactivate G1 checkpoint function. Even when focused on
gene expression that distinguishes G1 checkpoint-effective
and -defective lines, the analysis tools placed the genetically
modified NHM2 lines with the parental NHM2 strain and
the other checkpoint-effective NHMs. Melanoma lines with
defects in G1 checkpoint function must display alterations in
gene expression beyond simply inactivation of p53. When
considering the melanoma lines using the entire data set,
the Bayesian analysis tool correctly assigned G1 checkpoint
function in 13 out of 16 cases for a correct classification rate
of 81%.
A different set of genes was associated with defective DNA
damage G2 checkpoint function. When G2 checkpoint
function was evaluated as a binary variable (effective versus
defective), SAM identified only four genes (FDRo0.1), while
the Bayesian method identified 149 genes (FDR¼0.05)
(Figure 7; see Supplementary Table S1 for gene lists). In the
leave-one-out analysis, the Bayesian method assigned the
left-out sample to the appropriate centroid in 76% of tests,
while SAM assigned the left-out sample to the appropriate
centroid in 69% of tests.
DISCUSSION
We hypothesized that cell lines derived from malignant
melanomas would display defects in cell cycle checkpoint
function in order for cells to proliferate with the chromosomal
instability that characterizes this malignancy. The results
G1 checkpoint
log2
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SAM, FDR<0.1, 26 genes Bayesian, FDR=0.05, 166 genes
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Figure 6. Signatures of gene expression that were correlated with defective G1 checkpoint function. Agilent 44K long-oligo microarrays were used to
monitor global gene expression in NHMs and melanoma lines. Cells were harvested in log-phase growth and levels of gene expression determined relative
to a universal reference. Left panel: unsupervised hierarchical cluster of genes that were determined by SAM to be correlated with G1 checkpoint function
(FDRo0.1). Right panel: unsupervised hierarchical cluster of genes that were determined by Bayesian analysis to be correlated with G1 checkpoint
function (FDR¼ 0.05). Heat maps are median-centered. Gene lists are reported in the Supplementary Table S1.
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indicated that in comparison to NHMs in secondary cultures,
the melanoma lines often displayed functional defects in
DNA damage cell cycle checkpoints that arrest cell division
in G1 or G2. These defects in checkpoint function were
associated with distinct patterns of gene expression.
Defective DNA damage checkpoint function in melanoma lines
Recent reports have demonstrated DNA damage and the
activation of DNA damage responses in melanomas and
dysplastic nevi (Gorgoulis et al., 2005; Warters et al., 2005).
While normal melanocyte nuclei displayed very few or no
foci of phosphorylated histone H2AX (g-H2AX), significantly
increased frequencies of melanoma and dysplastic nevus cell
nuclei displayed g-H2AX foci. Foci of g-H2AX expression
occur at sites of DNA DSBs (Rogakou et al., 1999; Bekker-
Jensen et al., 2006), suggesting that malignant melanocytes
and pre-malignant precursors experience increased levels of
DNA damage in comparison to normal melanocytes. Expres-
sion of g-H2AX also was associated with the presence of
activated forms of ATM, p53, and Chk2, demonstrating
activation of the DNA damage response (Bartkova et al.,
2005; Gorgoulis et al., 2005). This condition of enhanced
DNA damage and activation of the DNA damage response
was induced in normal human fibroblasts by expression of
gene products such as CDC6, cyclin E, and E2F1 that drive
cells into a precocious S phase and by activated oncogenes,
including H-RAS (Bartkova et al., 2005, 2006; Di Micco
et al., 2006). Normal cell proliferation, as induced by growth
factors in medium, did not cause DNA damage, suggesting
that the disregulated S phase was responsible (Bartkova et al.,
2005). This work forms the basis for a hypothesis that
activated oncogenes, such as N-RAS and B-RAF, force cells to
enter a precocious S phase, producing a condition of
replication stress that leads to the development of DNA
DSB. The resulting DNA damage response includes activa-
tion of ATM and p53 to arrest the growth of cells with
damaged DNA. Cancer emerges under these conditions as
checkpoint control mechanisms that limit proliferation of
cells with damaged DNA are degraded, permitting the
expansion of clones with genetic instability. Activation of
the DNA damage response by oncogenes also was associated
with a G2 arrest (Bartkova et al., 2005), suggesting that the
G2 checkpoint represents a barrier to carcinogenesis and
cells with defects in G2 checkpoint function may display a
growth advantage at early stages of carcinogenesis.
The DNA damage G1 checkpoint requires ATM signaling
to activate p53 and induce expression of the cyclin-
dependent kinase inhibitor p21Waf1. This signaling pathway
appeared to be intact and effective in secondary cultures of
NHMs, as reported previously (Marrot et al., 2005; Sun et al.,
2005). While p53 is a central component of this checkpoint,
p53 mutations are uncommon in malignant melanomas,
being scored in 10–25% of tumors (Daniotti et al., 2004).
However, mutations in genes other than p53 also can affect
DNA damage G1 checkpoint function. For example, in-
activation of RB has been shown to ablate the G1 checkpoint
response to DNA damage (Demers et al., 1994). Given the
large number of gene products that participate in checkpoint
signaling upstream and downstream of p53, a variety of
genetic alterations could ablate or attenuate G1 checkpoint
function. A study of several uveal melanoma lines found that
IR treatment induced the activation of p53, but the p53-
dependent induction of p21Waf1 or BAX was defective (Sun
et al., 2005). Another study of radioresistant melanoma lines
identified a defect in post-translational modification of p53 in
response to radiation treatment (Satyamoorthy et al., 2000).
The current analysis detected a functional deficit in the G1
checkpoint in 69% of the melanoma lines tested, and in the
four epithelial-like melanoma lines with wild-type N-RAS
and B-RAF. By global analysis of gene expression, this
functional defect was associated with reduced basal levels of
expression of two p53-responsive genes, p21Waf1 and DDB2.
As radioresistance is often associated with defective signaling
in the p53 pathway, it is likely that the lines with defective G1
checkpoint function are radioresistant.
Analysis of checkpoint gene expression using tissue arrays
has been used to define a set of protein markers (Ki-67, p16,
Bcl-6, and p21Waf1) that predicts clinical outcome for
malignant melanoma (Alonso et al., 2004). Poor clinical
outcome (shorter survival in patients with vertical-growth-
phase melanoma) was associated with reduced expression of
DefEff
G2 checkpoint
Bayesian, FDR=0.05, 149 genes
Figure 7. Signature of gene expression that was correlated with defective
G2 checkpoint function. Unsupervised hierarchical cluster of genes that
were determined by Bayesian analysis to be correlated with G2 checkpoint
function (FDR¼ 0.05). The gene list is reported in the Supplementary
Table S1.
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p16 protein and elevated expression of Ki-67, Bcl-6, and
p21Waf1 proteins in primary tumor samples (Alonso et al.,
2004). Our analyses showed that G1 checkpoint-defective
melanoma lines displayed reduced expression of p21Waf1
mRNA and protein. Thus, elevated expression of p21Waf1
mRNA or protein may be a biomarker for melanomas
with effective p53 signaling and G1 checkpoint function.
It is remarkable that enhanced expression of p21Waf1 was a
marker of adverse clinical outcome; however, in the same
clinical study (Alonso et al., 2004), elevated p21Waf1
expression was associated with increases in proliferation
markers, such as cyclin D1 and Ki-67, and the proliferation
marker Ki-67 was also found to predict clinical outcome. It is
notable from our study that G1 checkpoint-defective mela-
nomas displayed higher levels of expression of CDC7 and
CKS1, genes that act to stimulate DNA synthesis. Together,
these results suggest a paradox in melanoma prognosis.
Enhanced proliferation is a marker of poor prognosis, yet
expression of the cyclin-dependent kinase inhibitor and
effector of p53-dependent inhibition of proliferation,
p21Waf1, also is a marker of poor prognosis. In most cancers
examined to date, inactivation of p53 function is associated
with poor prognosis. It is possible that in the study of Alonso
et al. (2004) expression of p21Waf1 served as a marker of cell
proliferation (Michieli et al., 1994) and not p53-dependent
checkpoint function.
The DNA damage G2 checkpoint prevents cells with
broken chromosomes from entering mitosis, thereby allowing
more time for repair of the breaks. Defects in G2 checkpoint
function in ataxia telangiectasia cells are associated with
significantly enhanced susceptibility to induction of chromo-
somal aberrations by IR (Zampetti-Bosseler and Scott, 1981)
and UV (Kaufmann and Wilson, 1994). Clearly, conditions of
in vitro cell culture do not select for defects in the G2
checkpoint as cancer lines with effective checkpoint function
can be isolated, as shown here. Defective G2 checkpoint
function in melanoma lines was associated with mutations in
the B-RAF oncogene but not mutations in N-RAS. As allelic
deletions in CDKN2A/INK4A locus are comparatively com-
mon in melanoma (Grafstrom et al., 2005), it will be of
interest to determine whether defects in G2 checkpoint
function sensitize melanocytes to UV-induced chromo-
somal aberrations and deletion of CDKN2A/INK4A alleles.
Enhanced UV clastogenesis could explain the earlier clinical
appearance of melanomas with B-RAF mutations (Thomas
et al., 2007).
Expression of oncogenic B-RAF in normal melanocytes
induces growth arrest through induction of p16 (Michaloglou
et al., 2005; Gray-Schopfer et al., 2006). Inactivation of p16
is common in melanomas, and four of six melanoma lines
that we examined had no detectable p16 protein (Figure 3).
However, factors other than p16 also appeared to contribute
to the B-RAF-induced growth arrest (Michaloglou et al.,
2005). Melanocyte lines that expressed hTERT and a
dominant-negative p53 proliferated with the mutant B-RAF
(Chudnovsky et al., 2005), suggesting that p53 also contri-
butes to oncogene-induced growth arrest in melanocytes.
It remains to be determined whether the defects in G2
checkpoint function seen in melanoma lines with mutant
B-RAF are a direct effect of the mutant oncogene or a
consequence of a secondary genetic alteration. Inactivation
of p16 or p53 does not appear to explain the defect as a
melanoma line with defective p53 signaling, and absence
of p16 protein expression (RPMI8332) displayed an effective
G2 checkpoint response to DNA damage. One alternative
secondary target is PTEN. Mutations in B-RAF are commonly
associated with inactivation of PTEN (Tsao et al., 2004),
which has been reported to regulate Chk1 and G2 checkpoint
function (Puc et al., 2005). It is interesting to note that the
B-RAF mutant melanoma line with an effective G2 checkpoint
response (A375) was reported to have a wild-type PTEN gene
(Tsao et al., 2004). Other potential targets for attenuation of
G2 checkpoint function are 14-3-3 proteins and Cdc25C
(Peng et al., 1997). Previous studies have demonstrated
that expression of mutant Ras oncogenes can attenuate G2
checkpoint function (Santana et al., 2002; Agapova et al.,
2004). However, expression of mutant N-RAS in melanoma
lines was not associated consistently with a significant defect
in G2 checkpoint function.
Signatures of defective DNA damage checkpoint function
in melanoma lines
Two methods were used to search for genes whose
expression was correlated with DNA damage checkpoint
function. SAM has been used to identify a signature of
defective p53 signaling in breast cancer (Troester et al., 2006)
that included several of the genetic elements in our G1
checkpoint list. The Bayesian method of analysis identified
more genes with a lower false discovery rate than SAM. The
Bayesian tool also more frequently assigned samples to the
correct category of checkpoint function. More studies will be
needed to determine whether the Bayesian tool is superior to
SAM for identifying genes whose expression is correlated
with selected biological states. The Bayesian G1 checkpoint
signature included many genes that are associated by gene
ontology with cell proliferation (see Supplementary Table
S1), as p53-defective melanoma lines grew faster than lines
with effective p53 signaling. The Bayesian G2 checkpoint
signature included the rather nonspecific gene ontology
biological functions of hydrolase activity and catalysis (see
Supplementary Table S1). To our knowledge, this was the first
attempt to identify a pattern of gene expression that predicts
DNA damage G2 checkpoint function. Future studies should
establish a minimal gene set for predicting DNA damage
checkpoint function in a larger sample of melanomas.
The expression of several p53-responsive genes was
correlated with expression of p21Waf1 in melanomas, includ-
ing DDB2. Germ-line inactivation of DDB2 in humans
causes xeroderma pigmentosum (complementation group E)
with significantly increased risk of development of skin
cancer including melanoma (Itoh et al., 2004). DDB2
encodes a factor that appears to aid in recruitment of other
repair factors to sites of damaged DNA in chromatin (Wang
et al., 2004). DDB2 also has recently been shown to regulate
expression of p53 protein; DDB2-defective cells displayed
reduced expression of p53 and concomitant attenuation of
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p53-dependent apoptosis and signaling in response to UV-
induced DNA damage (Itoh et al., 2003). These results
suggest that p53-defective melanomas also may express a
defect in repair of UV-induced DNA damage through
reduced expression of DDB2. Such a defect might enhance
melanoma progression in skin exposed to sunlight.
In summary, chromosomal instability in malignant mela-
noma may be attributed in part to acquired defects in cell
cycle checkpoints. Significant defects in DNA damage
checkpoint function were observed in 69% of melanoma
lines. Such defects may be common in melanomas and
identifiable by analysis of patterns of gene expression.
MATERIALS AND METHODS
Conditions of cell culture
Human melanocyte cultures were generated from neonatal
foreskin tissues, as described (Scott et al., 2005). Briefly, skin
sections were placed in a 35-mm dish containing complete
Dulbecco’s minimal essential medium with dispase (50 units per
ml) and incubated at 41C overnight. After peeling off the dermis, the
epidermis was placed in a 15-ml tube containing 2 ml of trypsin
(0.25%) and incubated at 371C for 30 minutes. After briefly
vortexing, 1 ml of calf serum was added and cells were collected
by sedimentation. The cell pellet was resuspended in 5 ml of
Medium 254 (Cascade Biologics, Portland, OR) containing one drop
of FCS. Cells were cultured in a T-25 flask and fed three times each
week with Medium 254 containing PMA-free Human Melanocyte
Growth Supplement (HMGS-2; Cascade Biologics, Portland, OR).
Secondary cultures of neonatal melanocytes were obtained by
releasing cells from primary culture dishes with trypsin-EDTA, and
then replating cells at lower cell density. For storage, melanocytes
were frozen in liquid nitrogen at 1 107 cells/ml in CS-C serum-free
cryopreservation medium (Cell Systems Corp., Kirkland, WA). Four
different melanocyte cultures were established for these studies. A
fifth foreskin melanocyte culture (NHM-5) was purchased from
Cambrex Corporation, Walkersville, MD. One melanocyte culture
(NHM-2) was infected with a replication-defective retrovirus that
transduced expression of HPV16E6 oncoprotein (NHM2-E6) or a
dominant-negative p53 (p53H179Q), along with a neomycin-
resistance gene (Simpson et al., 2005). Infected cells were selected
by growth for 2 weeks in culture medium containing 400 mg/ml
G418.
Melanoma cell lines were obtained from several sources (Table 1)
and grown as recommended by the supplier. All melanocytes and
melanoma cell lines were checked for mycoplasma contamination
using the GenProbes kit (Gen-Probe Inc., San Diego, CA), according
to the manufacturer’s recommended protocol. Cell lines with RLU
greater than twice background (approximately 4,000 RLU), consi-
dered contaminated with mycoplasma, were treated with Plasmocin
(Invitrogen Corp., Carlsbad, CA), according the manufacturer’s
recommended protocol, and then retested. No data are reported
for contaminated cultures. The F1-hTERT diploid human fibroblast
line was derived from foreskin and used in these studies, as
previously described (Heffernan et al., 2002).
The medical ethical committees of the University of North
Carolina at Chapel Hill and Rochester University approved all
described studies. The study was conducted according to the
Declaration of Helsinki Principles.
Mutational Analyses of B-RAF and N-RAS
The N-RAS/B-RAF mutational status was determined from genomic
DNA for the set of melanoma cell lines (Table 1). Genomic DNA
was isolated from cells using Genomic Tips kits (Qiagen, Valencia,
CA) and by following the manufacturer’s recommended protocol;
the mutational status of B-RAF at exons 11 and 15, and N-RAS at
codons 12, 13, 18, and 61 was determined as follows: PCR ampli-
fication utilized the following primers: B-RAF at exon 15, for:50-
TCATAATGCTTGCTCTGATAGGA-30, rev:50-GGCCAAA-AATTTAA
TCAGTGGA-30; B-RAF at exon 11, for:50-CTGTTTGGCTTGACTTG
AC-30, rev:50-GACTTGTCACAATGTCACC-30 (Thomas et al., 2004);
N-RAS at codons 12, 13, and 18, for:50-GACTGAGTACAAACTG
GTGG-30, rev:50-GGGCCTCACCTCTATGGTG-30; N-RAS at codon
61, for:5-GGTGAAACCTGTTTGTTGGA-30, rev:50-ATACACAGAGG
AAGCCTTC-30. PCR products were purified from 2% agarose gels
and DNA was sequenced using the forward PCR primers at the
University of North Carolina at Chapel Hill Automated DNA
Sequencing Facility on a 3100 Genetic Analyzer (Applied Biosys-
tems, Foster City, CA).
Quantification of DNA damage G1 and G2 checkpoint
functions
Exponentially growing cells in flasks with medium were irradiated
with 1.5 Gy 137Cs gamma rays (Gammacell40, MDS Nordion,
Ottawa, Canada) at a dose rate of 0.9 Gy per min. Sham-treated
controls were subjected to the same movements to and from the
irradiation facility but without irradiation. For quantification of G1
checkpoint function, cells were incubated with 10 mM BrdU at
6–8 hours post-irradiation to label S phase cells and then harvested
for two-channel flow cytometric analysis of incorporation of BrdU
and DNA content (Doherty et al., 2003). The fraction of BrdU-
labeled nuclei within the first half of the S phase (2–3N DNA
content) in irradiated cell preparations was expressed as a
percentage of the equivalent fraction in sham-treated controls as a
quantitative measure of DNA damage G1 checkpoint function. For
quantification of G2 checkpoint function, cells were incubated for
2 hours post-irradiation, and then harvested for determination of
mitotic fraction by flow cytometry, using anti-phospho-histone H3
antibody to label mitotic cells (Doherty et al., 2003). DNA damage
G2 checkpoint function was quantified as the mitotic fraction in
irradiated cells expressed as a percentage of the mitotic fraction
in sham-treated controls. For statistical comparisons between mela-
noma cell lines and NHMs, data were log-transformed and com-
pared by Student’s t-test, with Dunnett’s adjustment for multiple
comparisons.
Western immunoblot analyses
Logarithmically growing cells were seeded at 106 per 100-mm dish
and incubated for 40 hours. Cultures were treated with IR as
described above and incubated for 2, 6, and 24 hours at 371C.
Controls were harvested at 6 hours after sham treatment. Cells were
harvested by trypsinization, washed once in PBS, and resuspended
in 10 mM sodium phosphate buffer, pH 7.2, 1 mM EDTA, 1 mM EGTA,
150 mM NaCl, 1% NP40, supplemented with 1 protease inhibitor
cocktail (Sigma, St Louis, MO). Protein concentrations were
determined using the Bio-Rad DC Protein Assay (Bio-Rad Labora-
tories, Hercules, CA). Samples containing equal amounts of protein
were mixed with an equal volume of 2 Laemmli sample buffer
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(125 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol) containing 5%
b-mercaptoethanol, heated in boiling water, and separated by
SDS-polyacrylamide gel electrophoresis. Proteins were transferred
to nitrocellulose and probed with antibodies against various proteins
and phosphorylation epitopes that are associated with cell cycle
checkpoint function including p53 (Santa Cruz Biotechnology, Santa
Cruz, CA), phospho-ser15-p53 (Cell Signaling Technology, Danvers,
MA), Chk2 (Oncogene Research Products, Cambridge, MA),
phospho-ser68-Chk2 (Cell Signaling Technology), p21Waf1 (Lab-
vision Corp., Fremont, CA), Chk1 (Santa Cruz Biotechnology),
phospho-ser317-Chk1 (Cell Signaling Technology), ATM (Bethyl
Laboratories, Montgomery, TX), ATR (Bethyl Laboratories), NBS1
(Bethyl Laboratories), and Myt1 (Upstate Biotechnology, Lake
Placid, NY). Proteins were detected with horseradish peroxidase-
conjugated secondary antibodies, using the Amersham ECL reagent
(Amersham Pharmacia Biotech Inc., Piscataway, NJ). Films were
scanned using a DuoScan T1200 (Agfa Div., Bayer Corp., Ridgefield
Park, NJ) to produce JPEG images. These images were then analyzed
for pixel intensity using the AlphaEaseFC TM software (Alpha
Innotech Corp., San Leandro, CA). The relative pixel intensity was
normalized to the signal detected with extracts (included on every
blot) prepared from a sham-treated, human diploid fibroblast line
immortalized by ectopic expression of telomerase (F1-hTERT).
Microarray analysis
RNA was isolated from exponentially growing cultures using a
commercial (Qiagen) kit. Cellular RNA was labeled with Cy5-dUTP
and a pooled reference RNA preparation (Stratagene, La Jolla, CA)
was labeled with Cy3-dUTP by the manufacturer’s suggested
methods, using the Agilent low-RNA input linear amplification kit.
The Cy3- and Cy5-labeled samples were quantified, combined, and
then hybridized overnight at 651C to a 44,000-element human
genome 60-mer oligonucleotide microarray (G4112A, Agilent
Technologies, Palo Alto, CA). Arrays were then washed and scanned
using a GenePix 4000B scanner (Axon Instruments, Foster City, CA).
Images were gridded and quantified using GenePix Pro 5.1 software
(Molecular Devices Corp, Sunnyvale, CA). Scanned, gridded images
were uploaded to the UNC microarray database (http://genome.
unc.edu/). All primary data from this work are available at that site and
have been deposited into the gene expression omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) under accession number GSE7469.
The array data were retrieved from the UNC microarray database,
under the following criteria: (1) only reliable spots, as determined by
the array scanning software and the array manufacturer, were
selected; (2) only those spots whose channels 1 and 2 Lowess
normalized values wereX30 were selected; and (3) only genes with
greater than 70% complete data were selected. In the end, a total of
23,221 genes were selected for analysis.
SAM (Tusher et al., 2001) was applied to the gene lists using a
binary analysis, in which NHMs and melanoma lines were separated
into two classes, checkpoint-effective and checkpoint-defective.
NHMs and melanoma lines with levels of IR-induced cell cycle
arrest that were less than the median were considered checkpoint-
defective, those with levels of arrest greater than the median were
considered to be checkpoint-effective. SAM was applied to identify
genes that were differentially expressed between the two classes.
A second analytical tool based on Bayesian statistical theory was
also applied, to identify genes that distinguished the two classes. The
log-transformed gene expression values for the effective and
defective groups were assumed to follow normal distributions with
different group means and a common variance. Common non-
informative priors were applied to the unknown group means and
variance for each gene. The test for equality of the group means on
each gene was performed using the Bayes factor, and the multiple
testing adjustments in the Bayesian analysis were conducted as
described (Newton et al., 2004) with a 0.05 FDR.
Once supervised gene lists were identified, hierarchical cluster-
ing analysis was conducted using the program Cluster (http://
rana.lbl.gov/EisenSoftware.htm) to perform median-centered, aver-
age-linkage clustering. Clusters were visualized using Treeview.
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